Pasithea Therapeutics Priced $5M Private Placement of $1.2M Shares At $4.10/Share to Advance Next-Gen Cancer Treatments
Portfolio Pulse from Benzinga Newsdesk
Pasithea Therapeutics Corp. (NASDAQ:KTTA) announced a $5 million private placement to fund next-gen cancer treatments. The offering includes 1.2 million shares at $4.10 each, with accompanying warrants. Proceeds will support working capital and corporate purposes.
September 27, 2024 | 7:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pasithea Therapeutics is raising $5 million through a private placement to fund its cancer treatment development. The offering includes shares and warrants, potentially impacting stock price.
The private placement provides Pasithea with significant capital to advance its cancer treatment pipeline, which could positively impact investor sentiment and the stock price. The issuance of new shares and warrants may also affect the stock's supply and demand dynamics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100